Key Health News Updates: FDA Approvals, Recalls, and Novel Treatments

This summary highlights the latest in health news including the FDA's approval of a nasal spray alternative to EpiPen, Perrigo's recall of infant formula, France's extension of bluetongue vaccinations, challenges for vape developers for migraines and asthma, FDA's decision on MDMA-based PTSD treatment, a human case of swine flu in Michigan, and FDA's extended review of Humacyte's blood vessel implant.

Recent headlines in health news spotlight several key developments. The FDA has sanctioned ARS Pharmaceuticals' nasal spray, neffy, as the first non-needle alternative for allergic reactions, offering a new option to EpiPen users. This marks a significant advancement in emergency allergy treatments.

Meanwhile, Perrigo has issued a voluntary recall of 16,500 cans of its infant formula due to unspecified concerns, affecting products sold at H-E-B Grocery Company and CVS. This precaution underscores the importance of safety in infant nutrition.

In response to fresh bluetongue virus outbreaks in Europe, French authorities are ramping up their vaccination efforts for ruminants to curb the disease's spread. The initiative follows recent detections near the Belgian border.

On another front, North American companies like Qnovia and MIIST Therapeutics are developing vape-like devices to treat migraines and asthma, but face skepticism from health authorities and potential users regarding this new method of drug delivery.

In more regulatory news, the FDA has withheld approval for an MDMA-based treatment for PTSD, citing insufficient data from developer Lykos Therapeutics. MDMA, known as ecstasy, has been under consideration for mental health therapy.

Additionally, the Michigan Department of Health and Human Services has reported a human case of swine flu, with investigations ongoing to determine the source of exposure.

Lastly, Humacyte announced that the FDA has prolonged the review period for its blood vessel implant, a setback that led to a significant drop in the company's stock prices.

(With inputs from agencies.)